Panome Bio, a biotechnology research startup based in Saint Louis, MO, has secured an undisclosed amount in funding in a recent investment round led by BioGenerator Ventures and Telegraph Hill Partners. The company's Next-Generation Metabolomics platform offers comprehensive workflows and personalized data analysis reports to help profile and discover biomarkers.

Panome Bio's platform is making major advancements in the metabolism field by going beyond pairwise comparisons and making complex experiments with large and complicated datasets possible. Cutting-edge technology and computational methods are used to extract only the biologically-relevant chemical compounds to give a clearer view of phenotype. The company provides a global and unbiased view of the metabolome through a suite of complementary LC/MS assays that captures the breadth of diverse metabolites in biological systems.

Panome Bio can complement metabolomics data with proteomics to better understand pathways and metabolism through its partnership with Somalogic. Somalogic's SomaScan® 7K Assay is a high-throughput proteomics assay that screens 7,000 proteins per sample simultaneously.

With this latest funding, Panome Bio aims to further develop its platform and expand its capabilities in the biotechnology research industry.

For more information check our latest funding round: https://founderlodge.com/round/Panome-Bio-raises-0-Unknown-2023-03-16-Edward-Weinstein-MTA5NTM